The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat
subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor …

Tonic signaling of chimeric antigen receptor (CAR), ie, the spontaneous CAR activation in
the absence of tumor antigen stimulation, is considered to be a pivotal event controlling CAR …

Chimeric antigen receptor (CAR)-T cells showed great activity in hematologic malignancies.
However, heterogeneous antigen expression in tumor cells and suboptimal CAR-T-cell …

Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are
engineered to recognize and kill cancer cells, has achieved remarkable success in some …

Chimeric antigen receptor (CAR) T cells and natural killer (NK) cells are genetically
engineered immune cells that can detect target antigens on the surface of target cells and …

Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor
outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising …

Human natural killer T cells (NKTs) are innate-like T lymphocytes increasingly used for
cancer immunotherapy. Here we show that human NKTs expressing the pro-inflammatory …

Background Chimeric antigen receptor (CAR)-T cell therapy has established itself as a
potent therapeutic option for certain patients with relapsed/refractory (R/R) hematologic …

Combining synthetic biology with adoptive T-cell transfer has led to promising advances in
the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), diffuse …